

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number		10/535,000	
			Filing Date		May 16, 2005	
			First Named Inventor		Masakazu HATANO	
			Group Art Unit		1617	
			Examiner Name		Gigi Georgiana HUANG	
Sheet	1	of	3	Attorney Docket Number		05318/HG

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)
	1	2005/0043412	A1	ICHIKAWA et al.	02-24-2005

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Country Code	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)	Translation	
							Yes	Abstract Only
	2	WO	95/28387	A1	YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.	10-26-1995	a	
	3	EP	0 757 038	A1	YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.	02-05-1997		
	4	JP	2004-513148	A	PHARMACIA AB	04-30-2004	b	
	5	WO	02/38158	A1	PHARMACIA AB	05-16-2002		
	6	JP	63-79828	A	LABORATORIES MERCK, SHARP & DOHME	05-16-2002	c	
	7	EP	0 253 717	A1	LABORATORIES MERCK, SHARP & DOHME	01-20-1988		

## OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	8	Kyle A. PARROW et al., "Is It Worthwhile to Add Dipivefrin HC1 0.1% to Topical $\beta_1$ -, $\beta_2$ -blocker Therapy?", <u>Ophthalmology</u> , 96(9), 1338-1342 (1989).
	9	Mark B. ABELSON et al., "Sustained Reduction of Intraocular Pressure in Humans With the Calcium Channel Blocker Verapamil," <u>American Journal of Ophthalmology</u> , 105(2), 155-159 (1988).
	10	Kristine A. ERICKSON et al., "Verapamil Increases Outflow Facility in the Human Eye," <u>Exp. Eye Res.</u> , 61(5), 565-567 (1995).

Examiner Signature	/Gigi Huang/	Date Considered	04/21/2011
--------------------	--------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED OR TRANSMITTED: April 15, 2011

a EP 0 757 038 IS A RELATED FAMILY MEMBER OF WO 95/28387.

b WO 02/38158 IS A RELATED FAMILY MEMBER OF JP 2004-513148.

c EP 0 253 717 IS A RELATED FAMILY MEMBER OF JP 63-79828.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

Receipt date: 04/15/2011

10535000 - GAU: 1627

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number		10/535,000			
			Filing Date		May 16, 2005			
			First Named Inventor		Masakazu HATANO			
			Group Art Unit		1617			
			Examiner Name		Gigi Georgiana HUANG			
Sheet	2	of	3	Attorney Docket Number		05318/HG		
<b>U.S. PATENT DOCUMENTS</b>								
Examiner Initials*	Cite No.	Document Number	Kind Code	Patentee or Applicant		Publication Date (MM-DD-YYYY)		
<b>FOREIGN PATENT DOCUMENTS</b>								
Examiner Initials*	Cite No.	Country Code	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)	Translation	
							Yes	Abstract Only
<b>OTHER DOCUMENTS</b>								
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	11	Jing-Ming DONG et al., "cAMP-induced Morphological Changes Are Counteracted by the Activated RhoA Small GTPase and the Rho Kinase ROK $\alpha$ ," <u>J. Biol. Chem.</u> , 273, No. 35, 22554-22562 (1998).						
	12	Roser BUSCA et al., "Inhibition of Rho Is Required for cAMP-induced Melanoma Cell Differentiation," <u>Mol. Biol. Cell.</u> , 9(6), 1367-1378 (1998).						
	13	Michael DIESTELHORST, "Combined therapy of Pilocarpine or Latanoprost with Timolol Versus Latanoprost Monotherapy," <u>Surv. Ophthalmology</u> , 47, Suppl 1, S155-S161 (2002).						
	14	Philip P. ELLIS et al., "Aqueous Humor Pilocarpine and Timolol Levels After Instillation of the Single Drug or in Combination," <u>Invest. Ophthalmology &amp; Visual Science</u> , 32(3), 520-522 (1991).						
considered English translated portion only-first page lines 18 to 14 from the bottom	15	Asahi Kasei Press Release of August 20, 2002.*						
	16	CALBIOCHEM GENERAL CATALOG, 2002-2003.						
considered English text portion only	17	WAKO Bio Window, 38 March 2002.						
considered English translated portion only-P.225 left column, line 13-16	18	"Ryokunaisho to Ganatsu (Glaucoma and Intraocular Pressure)," <u>Ganka (Ophthalmology)</u> , No. 37.*						

Examiner Signature	/Gigi Huang/	Date Considered	04/21/2011
-----------------------	--------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED OR TRANSMITTED: April 15, 2011

\* PARTIAL ENGLISH-LANGUAGE TRANSLATION ENCLOSED.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

Receipt date: 04/15/2011

10535000 - GAU: 1627

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/535,000
				Filing Date	May 16, 2005
				First Named Inventor	Masakazu HATANO
				Group Art Unit	1617
				Examiner Name	Gigi Georgiana HUANG
Sheet	3	of	3	Attorney Docket Number	05318/HG

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Country Code	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)	Translation	
							Yes	Abstract Only
	19	JP	<del>2003-292442</del> 2003-29242	A	SANTEN PHARMACEUTICAL CO., LTD.	10-15-2003	d	

**OTHER DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature	/Gigi Huang/	Date Considered	04/21/2011
-----------------------	--------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED OR TRANSMITTED: April 15, 2011

d US 2005/0043412 IS A RELATED FAMILY MEMBER OF JP 2003-29242

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./